Psyence Biomedical Ltd (NASDAQ: PBM) is having a rough Wednesday morning. The stock is down about 15% in premarket trading, even as the broader market ticks higher — Nasdaq futures are up 0.71% and S&P 500 futures have gained 0.56%. So what gives?
The answer is pretty simple: profit-taking. Last Thursday, Psyence shares absolutely exploded, surging over 250% in a single session. That kind of move doesn't happen every day, and when it does, traders often lock in gains before the momentum fades. That's exactly what we're seeing now.
What Sparked the Rally?
The catalyst was a big one. President Donald Trump signed an executive order aimed at accelerating treatments for mental illness, with a specific focus on psychedelic drugs. The order includes a reported $50 million commitment for research into ibogaine — a psychedelic compound that's shown promise for treating addiction and PTSD.
Psyence Biomedical is uniquely positioned to benefit from this push. The company has a GMP-compliant ibogaine platform, and through its subsidiary PsyLabs, it manages the entire supply chain — sourcing, extraction, and purification — from Africa. Essentially, Psyence is a picks-and-shovels supplier in the ibogaine gold rush. The company already has stabilized, pharmaceutical-grade ibogaine doses in its inventory, ready to go.
Technical Check: Overbought and Stretched
After a 250% jump, it's no surprise that the stock's technicals look a bit extended. Psyence is trading 115.3% above its 20-day simple moving average and 68.7% above its 100-day SMA. That's a lot of distance from the trend, and it often invites snapback moves.
The relative strength index (RSI) is sitting at 78.66, which is firmly in overbought territory. That doesn't mean the stock can't go higher, but it does suggest that the buying pressure has been intense and a pullback or consolidation is more likely.
Zooming out, the longer-term picture is still fragile. Over the past 12 months, Psyence is down 56.60%. The stock is far below its 52-week high of $468.36 and just above the 52-week low of $1.92. That kind of volatility makes it hard to have much confidence in the trend, despite the recent rebound.
Key levels to watch: resistance at $8.00, a round number where sellers often show up, and support at $4.50, near the 20-day EMA where dip-buyers might step in.
As of Wednesday's premarket, Psyence shares were trading at $8.05, down 15.17%.
